MindRank Achieves Milestone in AI-Driven Anti-Aging Research as Dynamic Resilience Consortium Meeting Convenes Successfully in Germany
MindRank
AI Drug Developer
On October 16, 2025, the Dynamic Resilience consortium meeting, jointly initiated by Wellcome Leap and Temasek Trust, was successfully held in Germany.As the core collaborative R&D institution of the project, MindRank was invited to attend and deliver a special report., together with globally top scholars from the University of Oxford, the University of Oslo, the University of Cambridge, and Imperial College London, jointly explore the latest scientific research breakthroughs and technological innovations in the anti-aging field.
Dynamic Resilience is an internationally leading "AI + Anti-Aging" collaborative project dedicated to extending human healthspan by developing innovative therapies and drugs. The focus of this conference is "Application of Artificial Intelligence Knowledge Graphs in the Biological Field"and deeply discussed the significant milestone achievements made by MindRank in this direction.
MindRank, with its cutting-edge AI technology, has launchedSelf-developed Knowledge Graph Platform PharmkGPT. This platform has built an ultra-large-scale biomedical knowledge graph,Able toDeeply integrate multi-dimensional data such as genes, proteins, and diseases,Aimed at addressing key challenges in complex disease research, significantly improving the accuracy and reliability of AI models. Currently, this platform has beenNeurological diseases such as Alzheimer's diseaseAchieved outstanding results in the research.
In the future, MindRank plans to apply its technology to a broader range of aging-related disease areas, including acute brain failure syndromes such as delirium. By combining AI technology with deep biological insights, it aims to pioneer entirely new treatment pathways. MindRank's vision goes beyond merely extending lifespan; it is also focused on helping the elderly worldwide achieve healthier and higher-quality lives.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby enabling more diseases to be treatable and allowing more lives to regain health.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug research and development platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was included in Fortune magazine's IMPACT list as one of "China's most socially impactful entrepreneurial companies."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai